SG11201510503UA - Primary carboxamides as btk inhibitors - Google Patents
Primary carboxamides as btk inhibitorsInfo
- Publication number
- SG11201510503UA SG11201510503UA SG11201510503UA SG11201510503UA SG11201510503UA SG 11201510503U A SG11201510503U A SG 11201510503UA SG 11201510503U A SG11201510503U A SG 11201510503UA SG 11201510503U A SG11201510503U A SG 11201510503UA SG 11201510503U A SG11201510503U A SG 11201510503UA
- Authority
- SG
- Singapore
- Prior art keywords
- btk inhibitors
- primary carboxamides
- carboxamides
- primary
- btk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361839729P | 2013-06-26 | 2013-06-26 | |
US201361897577P | 2013-10-30 | 2013-10-30 | |
PCT/US2014/044247 WO2014210255A1 (en) | 2013-06-26 | 2014-06-26 | Primary carboxamides as btk inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201510503UA true SG11201510503UA (en) | 2016-01-28 |
Family
ID=52116191
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201802444XA SG10201802444XA (en) | 2013-06-26 | 2014-06-26 | Primary carboxamides as btk inhibitors |
SG11201510503UA SG11201510503UA (en) | 2013-06-26 | 2014-06-26 | Primary carboxamides as btk inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201802444XA SG10201802444XA (en) | 2013-06-26 | 2014-06-26 | Primary carboxamides as btk inhibitors |
Country Status (29)
Country | Link |
---|---|
US (4) | US9567339B2 (ro) |
EP (3) | EP3483167A1 (ro) |
JP (3) | JP6509838B2 (ro) |
KR (1) | KR102273997B1 (ro) |
CN (1) | CN105530932B (ro) |
AU (3) | AU2014302365B2 (ro) |
BR (1) | BR112015032330B1 (ro) |
CA (1) | CA2916298C (ro) |
CY (1) | CY1121146T1 (ro) |
DK (1) | DK3013337T3 (ro) |
ES (1) | ES2708998T3 (ro) |
HK (1) | HK1224202A1 (ro) |
HR (1) | HRP20190093T1 (ro) |
HU (1) | HUE040645T2 (ro) |
IL (2) | IL243332B (ro) |
LT (1) | LT3013337T (ro) |
ME (1) | ME03307B (ro) |
MX (1) | MX355943B (ro) |
NZ (1) | NZ754039A (ro) |
PL (1) | PL3013337T3 (ro) |
PT (1) | PT3013337T (ro) |
RS (1) | RS58273B1 (ro) |
RU (1) | RU2708395C2 (ro) |
SG (2) | SG10201802444XA (ro) |
SI (1) | SI3013337T1 (ro) |
TW (1) | TWI642657B (ro) |
UY (1) | UY35630A (ro) |
WO (1) | WO2014210255A1 (ro) |
ZA (1) | ZA201509012B (ro) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME03307B (me) * | 2013-06-26 | 2019-10-20 | Abbvie Inc | Primarni karboksamidi kao btk inhibitori |
CA2925624C (en) | 2013-09-30 | 2021-06-15 | Beijing Synercare Pharma Tech Co., Ltd. | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |
PL3461821T3 (pl) | 2014-10-24 | 2020-10-19 | Bristol-Myers Squibb Company | Związki indolo-karboksyamidu użyteczne jako inhibitory kinazy |
AR104259A1 (es) * | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
JP6473270B2 (ja) * | 2015-07-27 | 2019-02-20 | イーライ リリー アンド カンパニー | 7−フェニルエチルアミノ−4h−ピリミド[4,5−d][1,3]オキサジン−2−オン化合物及び変異体idh1阻害剤としてのそれらの使用 |
MA52119A (fr) | 2015-10-19 | 2018-08-29 | Ncyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
NZ741294A (en) * | 2015-11-17 | 2023-07-28 | Merck Patent Gmbh | Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity |
SG11201804152RA (en) | 2015-11-19 | 2018-06-28 | Incyte Corp | Heterocyclic compounds as immunomodulators |
SG11201804170RA (en) | 2015-12-17 | 2018-06-28 | Merck Patent Gmbh | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
EP4292650A3 (en) | 2015-12-22 | 2024-02-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
US20170335530A1 (en) * | 2016-05-23 | 2017-11-23 | Fatu K. Kofa | Pet waste vacuum and disposal device and method |
WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
CN105837993A (zh) * | 2016-06-01 | 2016-08-10 | 扬州兰都塑料科技有限公司 | 一种阻燃电力电缆用阻燃剂 |
CN106083707B (zh) * | 2016-06-01 | 2018-10-26 | 温州大学 | 一种非对称杂芳基硫醚的合成方法 |
CN105924840A (zh) * | 2016-06-01 | 2016-09-07 | 扬州兰都塑料科技有限公司 | 一种阻燃电力电缆 |
CN105884673B (zh) * | 2016-06-03 | 2018-05-11 | 温州大学 | 一种吲哚衍生物的合成方法 |
KR102685249B1 (ko) | 2016-06-20 | 2024-07-17 | 인사이트 코포레이션 | 면역조절제로서의 복소환식 화합물 |
MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
EP3497094B1 (en) | 2016-08-08 | 2023-02-15 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
PT3507282T (pt) * | 2016-09-02 | 2020-12-23 | Bristol Myers Squibb Co | Processo para a preparação de compostos de indol carboxamida |
JP2019534266A (ja) | 2016-10-14 | 2019-11-28 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 5員ヘテロアリール環の架橋した環誘導体、その製造方法およびその医学的使用 |
JP2020510624A (ja) | 2016-12-12 | 2020-04-09 | マルチビア インコーポレイテッド | がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物 |
US10308644B2 (en) | 2016-12-22 | 2019-06-04 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
PL3558990T3 (pl) | 2016-12-22 | 2022-12-19 | Incyte Corporation | Pochodne tetrahydroimidazo[4,5-c]pirydyny jako induktory internalizacji pd-l1 |
CN110382483A (zh) * | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的n-杂环化合物及其使用方法 |
EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
CN106928201B (zh) * | 2017-02-22 | 2019-08-23 | 江汉大学 | 合成2-乙烯基吲哚衍生物的方法 |
CN110831933A (zh) | 2017-05-25 | 2020-02-21 | 亚瑞克西斯制药公司 | 喹唑啉衍生物作为突变kras、hras或nras的调节剂 |
CN107098845A (zh) * | 2017-07-06 | 2017-08-29 | 贵州大学 | 一种5‑氰基‑6‑硝基吲哚的制备工艺 |
CN107721988A (zh) * | 2017-10-31 | 2018-02-23 | 无锡福祈制药有限公司 | 具有抗炎活性的异吲哚‑1‑酮类化合物 |
US11100492B2 (en) | 2018-02-19 | 2021-08-24 | Peter Garrett | General purpose re-loadable card aggregation implementation |
WO2019191707A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
DK3790877T3 (da) | 2018-05-11 | 2023-04-24 | Incyte Corp | Tetrahydro-imidazo[4,5-c]pyridinderivater som pd-l1-immunmodulatorer |
CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
KR20220075382A (ko) | 2019-09-30 | 2022-06-08 | 인사이트 코포레이션 | 면역조절제로서의 피리도[3,2-d]피리미딘 화합물 |
CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
JP2023526052A (ja) * | 2020-05-12 | 2023-06-20 | ピーエムブイ ファーマシューティカルズ, インコーポレイテッド | 変異体p53機能を復元させるための方法および化合物 |
CN115867346A (zh) * | 2020-06-02 | 2023-03-28 | Gb005股份有限公司 | 激酶抑制剂 |
BR112022025692A2 (pt) | 2020-06-19 | 2023-02-28 | Bayer Ag | 1,3,4-oxadiazóis e seus derivados como fungicidas |
CA3189850A1 (en) | 2020-08-04 | 2022-02-10 | Novartis Ag | Treatment of cll |
MX2023003564A (es) | 2020-09-30 | 2023-04-04 | Astrazeneca Ab | Compuestos y su uso en el tratamiento del cancer. |
WO2022094172A2 (en) * | 2020-10-30 | 2022-05-05 | Newave Pharmaceutical Inc. | Inhibitors of btk |
TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之結晶形式 |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
AU2021373044A1 (en) | 2020-11-06 | 2023-06-08 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
KR20230131251A (ko) * | 2021-01-12 | 2023-09-12 | 쥐비005 인코포레이티드 | 키나아제 억제제로서의 인돌 유도체 |
CN114957242B (zh) * | 2021-02-23 | 2023-08-22 | 药雅科技(上海)有限公司 | 吡啶并杂环类化合物作为激酶抑制剂的制备及其应用 |
CN114957241B (zh) * | 2021-02-23 | 2023-08-22 | 药雅科技(上海)有限公司 | 杂环类化合物作为激酶抑制剂的制备及其应用 |
CN114853723B (zh) * | 2021-02-03 | 2023-11-24 | 药雅科技(上海)有限公司 | 吲哚类化合物btk抑制剂的制备及其应用 |
US20240190864A1 (en) * | 2021-02-03 | 2024-06-13 | Ya Therapeutics Inc | Bruton's Tyrosine Kinase (BTK) INHIBITOR AND APPLICATION THEREOF |
CN114853752B (zh) * | 2021-02-03 | 2023-08-22 | 药雅科技(上海)有限公司 | Btk抑制剂吡啶并杂环类化合物的制备及其应用 |
WO2022228302A1 (en) * | 2021-04-25 | 2022-11-03 | Bionova Pharmaceuticals (Shanghai) Limited | Heteroaromatic carboxamide compounds and its use |
CN115521313B (zh) * | 2021-06-24 | 2023-11-03 | 山东大学 | 一种降解btk蛋白的化合物及其制备方法和应用 |
IL314122A (en) | 2022-01-27 | 2024-09-01 | Pmv Pharmaceuticals Inc | Deuterium-converted compounds to restore mutant P53 activity |
WO2023227080A1 (zh) * | 2022-05-25 | 2023-11-30 | 百极弘烨(南通)医药科技有限公司 | 一种protac化合物、含其的药物组合物及其制备方法和应用 |
WO2023250431A2 (en) * | 2022-06-22 | 2023-12-28 | Children's Hospital Medical Center | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof |
WO2024081748A2 (en) * | 2022-10-12 | 2024-04-18 | Maze Therapeutics, Inc. | Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4025510A (en) * | 1975-12-01 | 1977-05-24 | E. I. Du Pont De Nemours And Company | 2,4-Diaryl[1,3,4H]thiadiazines fused to quinoxalines |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
DE10022925A1 (de) * | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
WO2003009852A1 (en) * | 2001-07-24 | 2003-02-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2004041285A1 (en) * | 2002-10-31 | 2004-05-21 | Amgen Inc. | Antiinflammation agents |
US7329764B2 (en) | 2003-07-31 | 2008-02-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substitute benzothiophene compounds |
GB0400895D0 (en) * | 2004-01-15 | 2004-02-18 | Smithkline Beecham Corp | Chemical compounds |
KR100796965B1 (ko) * | 2004-05-04 | 2008-01-22 | 에프. 호프만-라 로슈 아게 | Ikk 저해제로서의 티에노피리딘 |
BRPI0511874A (pt) | 2004-06-09 | 2008-01-15 | Glaxo Group Ltd | derivados da pirrolopiridina |
TW200626142A (en) * | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
US20090275570A1 (en) | 2005-04-06 | 2009-11-05 | Astrazeneca Ab | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors |
CN101189243A (zh) * | 2005-04-06 | 2008-05-28 | 阿斯利康(瑞典)有限公司 | 取代的杂环及其作为chk1、pdk1和pak抑制剂的应用 |
WO2007005534A2 (en) * | 2005-06-30 | 2007-01-11 | Smithkline Beecham Corporation | Chemical compounds |
US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
US20090275619A1 (en) | 2006-04-03 | 2009-11-05 | BOUERES Julia | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors |
PE20081889A1 (es) * | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
US20080269193A1 (en) | 2007-04-16 | 2008-10-30 | Kenneth He Huang | Tetrahydroindole and Tetrahydroindazole Derivatives |
JP2010525046A (ja) * | 2007-04-27 | 2010-07-22 | アストラゼネカ アクチボラグ | 血液系腫瘍の治療のための方法 |
WO2008150490A2 (en) | 2007-06-01 | 2008-12-11 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriasis and crohn's disease |
CN101481380B (zh) * | 2008-01-08 | 2012-10-17 | 浙江医药股份有限公司新昌制药厂 | 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途 |
AR070317A1 (es) | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | Furo (3,2-c) piridina y tieno (3,2-c) piridinas |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
CA2747670A1 (en) * | 2008-12-19 | 2010-07-15 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
PL2473049T3 (pl) | 2009-09-04 | 2019-07-31 | Biogen Ma Inc. | Inhibitory kinazy tyrozynowej brutona |
WO2011075699A2 (en) | 2009-12-18 | 2011-06-23 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
US20110212461A1 (en) | 2010-02-26 | 2011-09-01 | Hans Marcus Ludwig Bitter | Prediction of cardiotoxicity |
CA2799904A1 (en) | 2010-05-20 | 2011-11-24 | F. Hoffmann-La Roche Ag | Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors |
WO2011159857A1 (en) | 2010-06-16 | 2011-12-22 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
EP2592933B1 (en) | 2010-07-16 | 2017-04-05 | Anderson Gaweco | Mif inhibitors and their uses |
BR112013006016A2 (pt) | 2010-09-15 | 2016-06-07 | Hoffmann La Roche | compostos de azabenzotiazol, composições e métodos de uso |
FR2969151B1 (fr) * | 2010-12-17 | 2016-11-04 | Oreal | Derives du 4-amino et leur utilisation pour la coloration d'oxydation des fibres keratiniques. |
US9133164B2 (en) | 2011-04-13 | 2015-09-15 | Innov88 Llc | MIF inhibitors and their uses |
EP2561759A1 (en) * | 2011-08-26 | 2013-02-27 | Bayer Cropscience AG | Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth |
US9365566B2 (en) | 2012-03-27 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives |
ME03307B (me) * | 2013-06-26 | 2019-10-20 | Abbvie Inc | Primarni karboksamidi kao btk inhibitori |
-
2014
- 2014-06-26 ME MEP-2019-21A patent/ME03307B/me unknown
- 2014-06-26 RS RS20190083A patent/RS58273B1/sr unknown
- 2014-06-26 SI SI201431050T patent/SI3013337T1/sl unknown
- 2014-06-26 CA CA2916298A patent/CA2916298C/en active Active
- 2014-06-26 WO PCT/US2014/044247 patent/WO2014210255A1/en active Application Filing
- 2014-06-26 SG SG10201802444XA patent/SG10201802444XA/en unknown
- 2014-06-26 MX MX2015017973A patent/MX355943B/es active IP Right Grant
- 2014-06-26 LT LTEP14817453.5T patent/LT3013337T/lt unknown
- 2014-06-26 NZ NZ754039A patent/NZ754039A/en unknown
- 2014-06-26 RU RU2016102137A patent/RU2708395C2/ru active
- 2014-06-26 ES ES14817453T patent/ES2708998T3/es active Active
- 2014-06-26 EP EP18202730.0A patent/EP3483167A1/en not_active Withdrawn
- 2014-06-26 HU HUE14817453A patent/HUE040645T2/hu unknown
- 2014-06-26 EP EP14817453.5A patent/EP3013337B1/en active Active
- 2014-06-26 EP EP21194489.7A patent/EP4008328A1/en active Pending
- 2014-06-26 SG SG11201510503UA patent/SG11201510503UA/en unknown
- 2014-06-26 UY UY0001035630A patent/UY35630A/es active IP Right Grant
- 2014-06-26 DK DK14817453.5T patent/DK3013337T3/en active
- 2014-06-26 TW TW103122168A patent/TWI642657B/zh active
- 2014-06-26 BR BR112015032330-8A patent/BR112015032330B1/pt active IP Right Grant
- 2014-06-26 CN CN201480047196.8A patent/CN105530932B/zh active Active
- 2014-06-26 KR KR1020167002152A patent/KR102273997B1/ko active IP Right Grant
- 2014-06-26 AU AU2014302365A patent/AU2014302365B2/en active Active
- 2014-06-26 PT PT14817453T patent/PT3013337T/pt unknown
- 2014-06-26 PL PL14817453T patent/PL3013337T3/pl unknown
- 2014-06-26 US US14/315,504 patent/US9567339B2/en active Active
- 2014-06-26 JP JP2016524175A patent/JP6509838B2/ja active Active
-
2015
- 2015-12-10 ZA ZA2015/09012A patent/ZA201509012B/en unknown
- 2015-12-24 IL IL243332A patent/IL243332B/en active IP Right Grant
-
2016
- 2016-11-01 HK HK16112545.7A patent/HK1224202A1/zh unknown
-
2017
- 2017-01-05 US US15/398,978 patent/US20170174624A1/en not_active Abandoned
-
2019
- 2019-01-16 HR HRP20190093TT patent/HRP20190093T1/hr unknown
- 2019-01-18 CY CY20191100073T patent/CY1121146T1/el unknown
- 2019-02-08 AU AU2019200901A patent/AU2019200901A1/en not_active Abandoned
- 2019-04-02 JP JP2019070362A patent/JP6770127B2/ja active Active
- 2019-05-23 US US16/421,006 patent/US20190284135A1/en not_active Abandoned
- 2019-06-05 IL IL267101A patent/IL267101A/en unknown
-
2020
- 2020-09-24 JP JP2020159339A patent/JP2021001212A/ja active Pending
-
2021
- 2021-02-11 US US17/173,613 patent/US20210179556A1/en not_active Abandoned
- 2021-03-08 AU AU2021201463A patent/AU2021201463A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267101A (en) | Primary carboxamides as btk inhibitors | |
IL279682A (en) | Benzoquinolone compounds as VMAT2 inhibitors | |
EP2948458A4 (en) | BTK INHIBITORS | |
EP2948431A4 (en) | BTK INHIBITORS | |
EP3082809A4 (en) | Btk inhibitors | |
HK1216531A1 (zh) | 新的抑制劑 | |
EP3082811A4 (en) | Btk inhibitors | |
RS64292B1 (sr) | Fotobioreaktor | |
EP3632467C0 (en) | INHIBITORS OF COMPLEMENT FACTOR H | |
HK1222339A1 (zh) | 金屬-β-內酰胺酶的抑制劑 | |
HK1221645A1 (zh) | 的苯並喹啉抑制劑 | |
IL240763A0 (en) | The halopyrazoles as thrombin inhibitors | |
GB201301346D0 (en) | Well completion | |
GB201322992D0 (en) | New Process | |
GB201317756D0 (en) | New process | |
GB201313211D0 (en) | New process | |
GB201305503D0 (en) | Inhibitor | |
GB201300961D0 (en) | New processes |